Jason McGrath
Overview
Explore the profile of Jason McGrath including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
60
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dowling G, Daly G, Hegarty A, Flanagan M, Ola M, Fallon R, et al.
Cancer Commun (Lond)
. 2024 Dec;
45(2):198-202.
PMID: 39676516
No abstract available.
2.
Jagust P, Powell A, Ola M, Watson L, de Pablos-Aragoneses A, Garcia-Gomez P, et al.
J Natl Cancer Inst
. 2024 Jun;
116(10):1632-1644.
PMID: 38852945
Background: Breast cancer brain metastasis is a rising occurrence, necessitating a better understanding of the mechanisms involved for effective management. Breast cancer brain metastases diverge notably from the primary tumor,...
3.
Daly G, Naidoo S, Alabdulrahman M, McGrath J, Dowling G, AlRawashdeh M, et al.
Curr Oncol Rep
. 2024 Jun;
26(8):890-903.
PMID: 38822929
Purpose Of Review: Homologous recombination repair deficiency (HRD) increases breast cancer susceptibility and influences both prophylactic and active management of breast cancer. This review evaluates HRD testing and the therapeutic...
4.
Daly G, Dowling G, Hamza E, AlRawashdeh M, Hegarty A, Naz T, et al.
Clin Breast Cancer
. 2024 May;
24(6):510-518.e4.
PMID: 38821743
Background: There have been ongoing attempts to de-escalate surgical intervention in older breast cancer patients in recent years. However, there remains ongoing hesitancy amongst surgeons to de-implement axillary staging in...
5.
Ali-Thompson S, Daly G, Dowling G, Kilkenny C, Cox L, McGrath J, et al.
Front Oncol
. 2024 May;
14:1355353.
PMID: 38769947
Aim: The overamplification of human epidermal growth factor (HER2) in breast cancer (BC) has been the subject of numerous research publications since its discovery in 1987. This is the first...
6.
Daly G, Alrawashdeh M, McGrath J, Dowling G, Cox L, Naidoo S, et al.
Curr Oncol Rep
. 2024 Jan;
26(2):103-113.
PMID: 38236558
Purpose Of Review: In the last decade, poly (ADP-ribose) polymerase (PARP) inhibitors have been approved in the treatment of several cancers, such as breast and ovarian cancer. This article aims...
7.
Davern M, Donlon N, OConnell F, Gaughan C, ODonovan C, McGrath J, et al.
J Cancer Res Clin Oncol
. 2022 Nov;
149(8):5377-5395.
PMID: 36445478
Aim: Use of immune checkpoint blockade to enhance T cell-mediated immunity within the hostile tumour microenvironment (TME) is an attractive approach in oesophageal adenocarcinoma (OAC). This study explored the effects...
8.
McGrath J, Kane L, Maher S
Cells
. 2022 Jul;
11(15).
PMID: 35892591
Radioresistance remains a significant challenge in treating pancreatic ductal adenocarcinoma (PDAC), contributing to the poor survival rates of this cancer. MicroRNAs (miRs) are small non-coding RNA molecules that may play...
9.
Davern M, Fitzgerald M, Buckley C, Heeran A, Donlon N, McGrath J, et al.
Transl Oncol
. 2022 Mar;
19:101381.
PMID: 35245832
Recent studies have demontrated that immune checkpoint receptors are expressed on the surface of oesophageal adenocarcinoma (OAC) cells and might confer a survival advantage. This study explores the role of...
10.
Davern M, O Brien R, McGrath J, Donlon N, Melo A, Buckley C, et al.
Sci Rep
. 2022 Mar;
12(1):3259.
PMID: 35228614
Chemotherapy upregulates immune checkpoint (IC) expression on the surface of tumour cells and IC-intrinsic signalling confers a survival advantage against chemotherapy in several cancer-types including oesophageal adenocarcinoma (OAC). However, the...